Deletion of GSTM1 and GSTT1 Genes and Lung Cancer Survival: a Systematic Review

Purpose The mechanisms of lung carcinogenesis are not fully understood. Not all smokers develop lung cancer, indicating that genetic variations and other environmental factors may play an important role in its development. The human glutathione S-transferases (GSTs) have been associated with an increased risk of lung cancer. Glutathione S-transferases are phase II biotransformation enzymes that play a role in detoxifying a wide range of exogenous agents including carcinogens but also anticarcinogenic drugs. Methods We assessed the effect of allelic deletions in the GSTM1 and GSTT1 genotypes on lung cancer overall survival through a systematic review of the scientific literature after applying predefined inclusion and exclusion criteria. Results Most of the included studies found no effect or a tendency to worse survival for individuals with deletion of GSTs. Conclusions Further studies are necessary to understand the magnitude of the effect of the deletion of both genes on lung cancer survival.

[1]  W. Jia,et al.  Role of GSTM1, GSTT1, and GSTP1 IIe105Val gene polymorphisms in the response to chemotherapy and overall survival of advanced non-small cell lung cancer. , 2016, Genetics and molecular research : GMR.

[2]  Han Xiao,et al.  Association of glutathione S-transferase (GST) genetic polymorphisms with treatment outcome of cisplatin-based chemotherapy for advanced non-small cell lung cancer in a Chinese population. , 2016, Genetics and molecular research : GMR.

[3]  W. Jia,et al.  Role of GSTM 1 , GSTT 1 , and GSTP 1 IIe 105 Val gene polymorphisms in the response to chemotherapy and overall survival of advanced non-small cell lung cancer , 2016 .

[4]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[5]  Kaixiong Liu,et al.  Predictive potential role of GSTs gene polymorphisms in the treatment outcome of advanced non-small cell lung cancer patients. , 2015, International journal of clinical and experimental medicine.

[6]  Shujuan Yang,et al.  Association of GSTs gene polymorphisms with treatment outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy. , 2015, International journal of clinical and experimental pathology.

[7]  Thirumurugan Ramasamy,et al.  GST M1-T1 null Allele Frequency Patterns in Geographically Assorted Human Populations: A Phylogenetic Approach , 2015, PloS one.

[8]  A. Fernández-Villar,et al.  Residential radon and lung cancer in never smokers. A systematic review. , 2014, Cancer letters.

[9]  Amin U. Khan,et al.  Risk factors for lung cancer in the Pakistani population. , 2014, Asian Pacific journal of cancer prevention : APJCP.

[10]  A. Ruano-Raviña,et al.  Lung cancer survival and deletion of GSTM1 and GSTT1 genes. A case-series from Spain , 2013 .

[11]  E. Smit,et al.  Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first‐line platinum‐gemcitabine chemotherapy , 2012, Cancer.

[12]  Yue Wang,et al.  Polymorphisms in GSTM1, CYP1A1, CYP2E1, and CYP2D6 are Associated with Susceptibility and Chemotherapy Response in Non-small-cell Lung Cancer Patients , 2012, Lung.

[13]  D. Schaid,et al.  Glutathione Pathway Genetic Polymorphisms and Lung Cancer Survival After Platinum-Based Chemotherapy , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[14]  S. Alpar,et al.  CYP and GST polymorphisms and survival in advanced non-small cell lung cancer patients. , 2010, Neoplasma.

[15]  D. Mavroudis,et al.  DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer. , 2009, Clinical lung cancer.

[16]  R. Ankathil,et al.  Glutathione S-transferase M1, T1 and P1 polymorphisms: susceptibility and outcome in lung cancer patients. , 2008, Journal of experimental therapeutics & oncology.

[17]  R. Weinshilboum,et al.  Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  J. Zwischenberger,et al.  CYP2E1 Polymorphism, Cigarette Smoking, p53 Expression, and Survival in Non-small Cell Lung Cancer: A Long Term Follow-up Study , 2004, Applied immunohistochemistry & molecular morphology : AIMM.

[19]  T. Vaughan,et al.  Glutathione S-transferase M1, T1, and P1 polymorphisms and survival among lung cancer patients. , 2003, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[20]  T. Lesnick,et al.  Genetic determinants of lung cancer short-term survival: the role of glutathione-related genes. , 2002, Lung cancer.

[21]  David Harrington,et al.  Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. , 2002, The New England journal of medicine.

[22]  M. Spiteri,et al.  Glutathione-S-transferase family of enzymes. , 2001, Mutation research.

[23]  L. Németh,et al.  Occupational asbestos exposure and lung cancer , 1999 .

[24]  R. Strange,et al.  The glutathione S-transferases: influence of polymorphism on cancer susceptibility. , 1999, IARC scientific publications.

[25]  L. Liotta,et al.  p53 mutation spectrum in relation to GSTM1, CYP1A1 and CYP2E1 in surgically treated patients with non-small cell lung cancer. , 1998, Pharmacogenetics.

[26]  M. Yamamoto,et al.  Prognostic significance of germ line polymorphisms of the CYP1A1 and glutathione S-transferase genes in patients with non-small cell lung cancer. , 1996, Cancer research.

[27]  J. Hayes,et al.  The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. , 1995, Critical reviews in biochemistry and molecular biology.